Cytosorbents Corporation
CTSO
$1.09
$0.021.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 81.25% | -237.77% | 43.66% | 31.95% | 7.39% |
| Total Depreciation and Amortization | -4.91% | -0.75% | -3.96% | 0.74% | -43.85% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 1,879.44% | -200.00% | -- |
| Total Other Non-Cash Items | -134.04% | 418.73% | -220.46% | -32.28% | 351.70% |
| Change in Net Operating Assets | 74.45% | -219.07% | 146.12% | -65.25% | -561.84% |
| Cash from Operations | -47.94% | 4.84% | 48.67% | 0.73% | 24.62% |
| Capital Expenditure | 96.97% | 54.38% | -733.52% | 59.73% | 52.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.00% | 62.48% | -44.29% | -24.21% | -102.48% |
| Cash from Investing | 62.00% | 58.38% | -148.87% | 5.59% | 6.55% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -600.00% | -- |
| Issuance of Common Stock | 3,993.53% | -- | -- | -100.00% | -99.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 92.71% | -- | -- |
| Cash from Financing | 3,993.53% | 268.59% | -101.01% | 1,819.94% | -104.68% |
| Foreign Exchange rate Adjustments | 124.46% | -224.30% | 222.06% | -1,303.45% | 105.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 239.10% | 13.27% | -157.18% | 187.82% | -199.18% |